FEMY Femasys Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
FEMY
—
—
Key stats
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 54
- List Date
- 2021-06-18
- CIK
- 0001339005
- Next Earnings
- 2026-11-13
- Headquarters
- Suwanee, GA
- Homepage
- https://www.femasys.com
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permane…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -25.06% | 34.51% | -25.90% | 7.27% | -15.94% | -5.02% |
| Feb | -- | 0.00% | -9.84% | 120.00% | 38.94% | 10.45% | 31.91% |
| Mar | -- | -15.04% | 1.40% | -17.11% | -18.83% | -21.90% | -14.30% |
| Apr | -- | -22.64% | -22.32% | -26.16% | -5.69% | -12.42% | -17.85% |
| May | -- | -5.52% | -24.16% | -9.23% | -24.79% | 0.78% | -12.58% |
| Jun | -32.42% | 41.76% | -30.73% | -0.87% | 16.36% | -44.69% | -8.43% |
| Jul | -10.43% | -15.42% | 11.76% | -3.42% | -11.54% | -35.59% | -10.77% |
| Aug | 2.58% | -6.08% | -23.13% | 3.54% | -56.67% | 15.49% | -10.71% |
| Sep | -13.01% | -34.30% | 562.22% | 1.83% | -11.88% | -33.74% | 78.52% |
| Oct | -3.75% | 15.60% | -61.95% | 18.75% | 69.71% | -32.86%* | 0.92% |
| Nov | -19.22% | -16.92% | -31.50% | -11.11% | 53.71% | -- | -5.01% |
| Dec | -16.67% | -25.62% | 4.84% | 0.00% | -35.46% | -- | -14.58% |
| Total | -65.00% | -75.41% | -21.99% | -3.50% | -43.22% | -88.29% | -49.57% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.82
SMA 50: $2.37
SMA 200: $6.35
Current: $1.41
EMA 12: $1.67
EMA 26: $1.94
MACD: -0.2631 | Signal: -0.0092
BEARISH
ADX (14): 41.20
STRONG TREND
+DI: 7.42
−DI: 29.90
Momentum Oscillators
RSI (14): 26.18
OVERSOLD
Stoch %K: 8.92
Stoch %D: 15.60
Williams %R: -93.79
Volume & Volatility
BB Upper: $2.29
BB Lower: $1.36
NEUTRAL
OBV: 47,416,977
Vol SMA 20: 114,584
Vol ROC: 66.20%
ATR: $0.20
True Range: $0.14
HV 20: 92.8%
HV 30: 79.9%
HV 60: 95.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is a comprehensive stock analysis report for FEMY:
Executive Summary
BULLISH/BEARISH: NEUTRAL (Confidence level: 6/10)
Key drivers: Strong recent news sentiment, expanding product portfolio, and partnership announcements.
Primary risks: High volatility, market uncertainty, and potential regulatory issues.
Investment thesis: FEMY is a growth-oriented stock with significant upside potential. Recent positive news headlines and partnership announcements have driven the stock higher, but high volatility and market uncertainty remain key risks.
Recent news sentiment impact: Positive news sentiment has been driving the stock higher, particularly in the last 6 months. The overall sentiment is POSITIVE (75%).
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - BEARISH
Medium-term (1-3 months) - NEUTRAL
Long-term (3-12 months) - BULLISH
Support/Resistance Levels:
- Resistance Level 1: $2.95 (EMA 12)
- Resistance Level 2: $3.16 (SMA 50)
- Support Level 1: $2.03 (Bollinger Bands Lower)
- Support Level 2: $2.76 (SMA 20)
Momentum Signals:
- RSI interpretation: NEUTRAL (42.85) - no clear buy or sell signal
- MACD signal: BEARISH crossover - bears in control
- Bollinger Bands position: SQUEEZE - price is compressed within the bands
Volume Analysis:
- Volume SMA 20: 2099026.15 (increasing)
- On-Balance Volume (OBV): 48969760.42 (increasing)
- Volume Rate of Change: -33.54% (decreasing) - potential signs of accumulation
News & Sentiment Analysis
Recent Headlines Summary:
- Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
- Partnership announcements and product launches driving positive sentiment
Sentiment Assessment: POSITIVE (75%)
Catalyst Identification: Upcoming earnings release, potential FDA approvals, and further partnership announcements
Market Narrative:
- Technical signals are bearish, but recent news headlines have driven the stock higher
- Volume indicators suggest institutional accumulation, which could support the stock price
Risk & Volatility Assessment
Beta Interpretation: High risk (beta 1.65)
Volatility Regime: High volatility - stock moves more than market
Options Market Signals:
- IV rank: N/A (no options data available)
- Put/call ratios: N/A (no options data available)
- Unusual activity: N/A (no options data available)
Generated
News
All FEMY news →
FEMY Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 2.0929
Alpha: -188.49%
Correlation: 0.2429
R-Squared: 5.9%
Stock Volatility: 109.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own FEMY
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $71K | #5902 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
FEMY Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
FEMY Insider Trading (Form 4)
Latest: 2026-08-11Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | Kathy Lee-Sepsick | Chief Executive Officer | Buy (P) | +15,625 | $3.20 | $50.0K | EDGAR |
| 2026-08-11 | Charles Larsen | Director | Grant (A) | +880 opt | — | EDGAR | |
| 2026-08-11 | John Charles Canning | Chief Operating Officer | Buy (P) | +4,375 | $3.20 | $14.0K | EDGAR |
| 2026-08-11 | Kenneth D. Eichenbaum | Director | Grant (A) | +880 opt | — | EDGAR | |
| 2026-08-11 | Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | Buy (P) | +3,125 | $3.20 | $10.0K | EDGAR |
| 2026-08-11 | Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | Grant (A) | +6,250 opt | — | EDGAR | |
| 2026-08-11 | Jeremy Alexander Sipos | Chief Technology Officer | Buy (P) | +3,125 | $3.20 | $10.0K | EDGAR |
| 2026-08-11 | Alistair Milnes | Director | Grant (A) | +880 opt | — | EDGAR | |
| 2026-08-11 | Edward R Uzialko | Director | Grant (A) | +880 opt | — | EDGAR | |
| 2026-08-11 | Dov Elefant | Chief Financial Officer | Buy (P) | +15,625 | $3.20 | $50.0K | EDGAR |
| 2026-04-01 | John Charles Canning | Chief Operating Officer | Grant (A) | +150,000 opt | — | EDGAR | |
| 2026-03-27 | Charles Larsen | Director | Grant (A) | +34,122 RSU | — | EDGAR | |
| 2026-03-27 | Dov Elefant | Chief Financial Officer | Grant (A) | +34,122 RSU | — | EDGAR | |
| 2026-03-27 | Kenneth D. Eichenbaum | Director | Grant (A) | +102,366 RSU | — | EDGAR | |
| 2026-03-27 | Kathy Lee-Sepsick | Chief Executive Officer | Grant (A) | +68,244 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
FEMY Insider Holdings
8 insiders · @ $1.41
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kathy Lee-Sepsick | Chief Executive Officer | 19,236 | $27.1K | $50.0K | 9 | 2026-08-11 |
| 2 | Dov Elefant | Chief Financial Officer | 15,625 | $22.0K | $50.0K | 10 | 2026-08-11 |
| 3 | Edward R Uzialko | Director | 7,898 | $11.1K | $1.30M | 6 | 2026-08-11 |
| 4 | Daniel Scott Currie | Chief Operating Officer | 5,425 | $7.6K | $0 | 5 | 2025-06-04 |
| 5 | John Charles Canning | Chief Operating Officer | 4,375 | $6.2K | $14.0K | 2 | 2026-08-11 |
| 6 | Jeremy Alexander Sipos | Chief Technology Officer | 3,125 | $4.4K | $10.0K | 2 | 2026-08-11 |
| 7 | Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | 3,125 | $4.4K | $10.0K | 2 | 2026-08-11 |
| 8 | Charles Larsen | Director | 3 | $4 | $91.0K | 9 | 2026-08-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
FEMY Board & Officers
As of SEC filings through Aug 11, 2026Directors 5
- Charles Larsen · since Jun 17, 2021
- Edward R Uzialko · since Jun 17, 2021
- Kathy Lee-Sepsick · since Jun 17, 2021
- Alistair Milnes · since Jun 14, 2023
- Kenneth D. Eichenbaum · on file since Mar 2026
Officers 6
- Kathy Lee-Sepsick · Chief Executive Officer · since Jun 17, 2021
- Dov Elefant · Chief Financial Officer · since Feb 28, 2022
- John Charles Canning · Chief Operating Officer · since Mar 30, 2026
- Kelley Stinson Nicholas · Chief Commercial Officer · since Jun 23, 2025
- Jeremy Alexander Sipos · Chief Technology Officer · since Dec 16, 2025
- Jeffrey Gerald Mifek · Chief Clinical-Medical Affairs · since Jul 6, 2026
Changes in the last 10 years (39)
| Jul 6, 2026 | Jeffrey Gerald Mifek became Chief Clinical-Medical Affairs |
| Mar 30, 2026 | John Charles Canning became Chief Operating Officer |
| Mar 20, 2026 | Kenneth D. Eichenbaum first on file as a director |
| Mar 18, 2026 | PharmaCyte Biotech, Inc. reported in an SEC filing no longer being a 10% owner |
| Mar 17, 2026 | Joshua Silverman left the board, per their own SEC filing |
| Dec 16, 2025 | Jeremy Alexander Sipos became Chief Technology Officer |
| Oct 13, 2025 | The company announced the departure of Daniel Scott Currie as Chief Operating Officer in an SEC filing |
| Jun 23, 2025 | Kelley Stinson Nicholas became Chief Commercial Officer |
| Feb 12, 2024 | Richard D. Spector became Chief Commercial Officer |
| Feb 2, 2024 | Daniel Scott Currie listed as Chief Operating Officer (previously Senior VP, Operations) in SEC filings |
| Nov 21, 2023 | PharmaCyte Biotech, Inc. became a 10% owner |
| Nov 21, 2023 | Joshua Silverman became a director |
| Nov 8, 2023 | The company announced the departure of Wendy Perrow from the board in an SEC filing |
| Nov 8, 2023 | The company announced the departure of Keith J Kendall from the board in an SEC filing |
| Nov 8, 2023 | The company announced the departure of Anne Morrissey from the board in an SEC filing |
| Jun 23, 2023 | Edward R Uzialko no longer listed as a 10% owner in SEC filings |
| Jun 14, 2023 | The company announced the departure of John Q Adams JR from the board in an SEC filing |
| Jun 14, 2023 | Keith J Kendall became a director |
| Jun 14, 2023 | Alistair Milnes became a director |
| Oct 10, 2022 | Christine E Thomas became SVP, Regulatory & Clinical |
| Feb 28, 2022 | Dov Elefant became Chief Financial Officer |
| Jan 19, 2022 | Wendy Perrow became a director |
| Jan 19, 2022 | The company announced the departure of William Benson Witte from the board in an SEC filing |
| Dec 17, 2021 | John Dyett no longer listed as a 10% owner in SEC filings |
| Sep 1, 2021 | Edward Evantash became Chief Medical Officer |
| Jun 21, 2021 | Gary Thompson first listed as VP, Finance & Administration in an SEC filing |
| Jun 17, 2021 | William Benson Witte became a director |
| Jun 17, 2021 | Kathy Lee-Sepsick became a director |
| Jun 17, 2021 | Kathy Lee-Sepsick became Chief Executive Officer |
| Jun 17, 2021 | John Q Adams JR became a director |
| Jun 17, 2021 | John Dyett became a director |
| Jun 17, 2021 | John Dyett became a 10% owner |
| Jun 17, 2021 | Hoskin Violet Alexandria Kelley became VP, Clinical & Medical Affairs |
| Jun 17, 2021 | Gary Thompson became a director |
| Jun 17, 2021 | Edward R Uzialko became a director |
| Jun 17, 2021 | Edward R Uzialko became a 10% owner |
| Jun 17, 2021 | Daniel Scott Currie became Senior VP, Operations |
| Jun 17, 2021 | Charles Larsen became a director |
| Jun 17, 2021 | Anne Morrissey became a director |
Not reported recently (6)
- Christine E Thomas · Last reported as SVP, Regulatory & Clinical in an SEC filing dated Jan 30, 2025
- Richard D. Spector · Last reported as Chief Commercial Officer in an SEC filing dated Feb 13, 2024
- John Dyett · Last reported as a director in an SEC filing dated Jun 10, 2022
- Edward Evantash · Last reported as Chief Medical Officer in an SEC filing dated Sep 9, 2021
- Gary Thompson · Last reported as VP, Finance & Administration in an SEC filing dated Jun 21, 2021
- Hoskin Violet Alexandria Kelley · Last reported as VP, Clinical & Medical Affairs in an SEC filing dated Jun 17, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
2 ETFs hold FEMY
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.